| 贝伐珠单抗在肿瘤治疗中的应用研究进展 |
| |
| 引用本文： | 周振兴. 贝伐珠单抗在肿瘤治疗中的应用研究进展[J]. 微生物学杂志, 2015, 0(7) |
| |
| 作者姓名： | 周振兴 |
| |
| 作者单位： | 1. 上海罗氏制药有限公司，上海 201203；2. 南京医科大学附属肿瘤医院江苏省肿瘤医院妇瘤科，江苏 南京 210009 |
| |
| 摘 要： | 贝伐珠单抗是一种重组人源化免疫球蛋白 G1 单克隆抗体，可通过抑制血管内皮生长因子活性及抗血管生成，达到抑制肿瘤生长的目的，目前已广泛用于结直肠癌、肺癌、卵巢癌等多种肿瘤的治疗，尤其是通过与基础化疗结合，能显著提高治疗的有效率以及延长肿瘤患者的无进展生存期和总生存期。综述贝伐珠单抗的抗肿瘤作用机制、在不同肿瘤治疗中的应用、用于肿瘤治疗时机与疗效差异以及不良反应和防治。
|
| 关 键 词： | 贝伐珠单抗；单克隆抗体；血管生成；抗肿瘤活性；无进展生存期；总生存期 |
R esearch Progress of Bevacizumab in Tumor Therapy |
| |
| ZHOU Zhenxing. R esearch Progress of Bevacizumab in Tumor Therapy[J]. Journal of Microbiology, 2015, 0(7) |
| |
| Authors: | ZHOU Zhenxing |
| |
| Affiliation: | 1. Roche Pharmaceutical Co. Ltd., Shanghai 201203, China; 2. Department of Gynecologic Oncology, Jiangsu Cancer Hospital, Cancer HospitalAffiliated to Nanjing Medical University, Nanjing 210009, China |
| |
| Abstract: | Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that suppresses tumor growth by inhibiting vascular endothelialgrowth factor and angiogenesis. It has been used widely in the treatment of several tumors, such as colorectal, lung and ovarian cancers, especially incombination of basic chemotherapy, which has been proved to significantly improve response rate, progression-free survival and overall survival. Theantitumor mechanism, application in the treatment of tumors, timing of intervention and the difference of efficacy as well as adverse reactions andtheir prevention and control for bevacizumab were reviewed. |
| |
| Keywords: | bevacizumab monoclonal antibody angiogenesis antitumor activity progression-free survival overall survival |
|
| 点击此处可从《微生物学杂志》浏览原始摘要信息 |
|
点击此处可从《微生物学杂志》下载全文 |
